Mechanisms of Adaptive Resistance to Targeted Therapy in RET-Aberrant Cancers.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39808501.
- Also identified by DOI 10.1158/1078-0432.CCR-24-3734.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The success of targeted therapies in oncogene-driven cancer is limited by adaptive or acquired treatment resistance, leading to disease progression. A recent study reports that YAP-dependent human epidermal growth factor receptor 3 (HER3) activation constitutes a therapeutic vulnerability of adaptive resistance to RET-targeted therapies in RET-altered cancers, highlighting a promising strategy to improve RET inhibitor tumor responses. See related article by Katayama et al., p. 1127.
Medical subject headings
- Proto-Oncogene Proteins c-ret
- Drug Resistance, Neoplasm
- Neoplasms